AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28186943
Drug: Picture booklet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picture booklet intervention used with a trained researcher and a carer present, used at least twice over 20 weeks.
Trial: 28186943
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (control group) with a booklet provided at the end of the study.
Trial: 25115507
Drug: Caffeine (split
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (split dose 2 × 3 mg kg(‐1))
Trial: 21626050
Drug: Antipyrine clearance
RxNorm normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipyrine clearance test (ACL) with oral antipyrine 10 mg/kg
Trial: 21626050
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m(2)/3‐weekly or 35 mg/m(2)/weekly)
Trial: 21626050
Drug: Docetaxel weekly
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel weekly patients
Trial: 31308037
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anti-infection treatment)
Trial: 25475768
Drug: 0.2% Chlorohexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% Chlorohexidine gel (Group 2)
Trial: 11571096
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg oral methyltestosterone (meT) in combination with 0.625 mg oral esterified estrogen (E)
Trial: 11571096
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg oral esterified estrogen (E) alone
Trial: 15101020
Drug: Aspirin 162
RxNorm normalized name: aspirin 162 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 162 mg
Trial: 9262254
Drug: Aspirin 40.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 40.5 mg
Trial: 30557879
Drug: Short-term steroid
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term steroid regimen (prednisolone 0.8-1.0 mg/kg/day for 4-6 weeks, then 0.5-0.6 mg/kg/alternate day for 4 weeks)
Trial: 30557879
Drug: Conventional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional steroid administration (control group, n = 140)
Trial: 22821285
Drug: Selenium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium intake (μg/day/1,000 kcal)
Trial: 22821285
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake (mg/day/1,000 kcal)
Trial: 21535123
Drug: Antenatal testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal testing initiation for medication-treated gestational diabetes
Trial: 18692175
Drug: Tolvaptan (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (15 mg, titratable to 30 or 60 mg) once daily for 30 days
Trial: 12185505
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy with CEOP-Bleo (cyclophosphamide 750 mg/m(2), vincristine 1.4 mg/m(2), prednisone 40 mg/m(2), epirubicin 70 mg/m(2), and bleomycin 10 mg/m(2)) every 21 days for six cycles followed by radiotherapy (35-45 Gy, mean 38 Gy)
Trial: 12185505
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy with mega CEOP-Bleo (cyclophosphamide 1000 mg/m(2), epirubicin 120 mg/m(2), vincristine, prednisone, and bleomycin at the same doses) every 21 days for six cycles followed by radiotherapy (35-45 Gy, mean 38 Gy)
Trial: 28749158
Drug: Trauma-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused cognitive behavioral therapy treatment (TF-CBT-anger)
Trial: 24755139
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g RBEP (rice bran exo‐biopolymer)
Trial: 24755139
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g placebo
Trial: 21909060
Drug: Glucose solution
RxNorm normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solution
Trial: 19227650
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with natural rubber latex (NRL) for 3 years
Trial: 12559481
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (N=9)
Trial: 2167800
Drug: Oral frusemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral frusemide
Trial: 7324942
Drug: 10-day treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day treatment with sulfafurazole
Trial: 7324942
Drug: 42-day treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 42-day treatment
Trial: 30679107
Drug: Four courses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four courses of S-1 (80 mg/day per m2 for 4 weeks followed by 2 weeks rest)
Trial: 30679107
Drug: Eight courses
RxNorm normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight courses of S-1 (80 mg/day per m2 for 4 weeks followed by 2 weeks rest)
Trial: 26858958
Drug: Peer support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer support intervention (additional to DMP), running over 24 months, including peer supporter recruitment, training, weekly physical exercise meetings, and monthly discussions on diabetes-related topics.
Trial: 20873252
Drug: magnetotherapy, manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: magnetotherapy, manual massage and exercise therapy
Trial: 15910951
Drug: Home visitation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home visitation by nurses in addition to standard treatment
Trial: 11876704
Drug: Bismuth-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based triple regimens (treatment group)
Trial: 11876704
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (no treatment group)
Trial: 10606847
Drug: Locobase(R) fatty
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locobase(R) fatty cream containing a mixture of 5% lactic acid and 20% propylene glycol (LPL)
Trial: 10606847
Drug: Essex(R) (Diprobase(R))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essex(R) (Diprobase(R)) cream (LPE)
Trial: 10606847
Drug: Locobase(R) fatty
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locobase(R) fatty cream containing 5% urea
Trial: 10606847
Drug: Locobase(R) fatty
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locobase(R) fatty cream containing 20% propylene glycol
Trial: 6085375
Drug: Nitrendipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (2 X 10 to 2 X 20 mg/day)
Trial: 6085375
Drug: Propranolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (2 X 80 to 2 X 160 mg/day)
Trial: 30473390
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of delayed start time and sleep education programme
Trial: 30309835
Drug: Tailored, therapist-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored, therapist-guided internet-based cognitive behavioral therapy (ICBT)
Trial: 23582138
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of fentanyl plus open-label boluses of fentanyl
Trial: 23582138
Drug: Placebo (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (continuous infusion of placebo plus open-label boluses of fentanyl)
Trial: 20872323
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral feeding
Trial: 18394499
Drug: Placebo (sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sham treatment with disconnected ultrasound and magnetotherapy equipment)
Trial: 16451396
Drug: Flexible treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible treatment schedule
Trial: 16451396
Drug: Fixed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed treatment schedule
Trial: 8015881
Drug: Amoxicillin/clavulanate (iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (iv 100 mg/kg/d, then oral 50 mg/kg/d after 48 hours afebrile)
Trial: 8015881
Drug: Benzylpenicillin (100,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzylpenicillin (100,000 IU/kg/d) + netilmicin (5 mg/kg/d) + metronidazole (30 mg/kg/d) (iv, then oral metronidazole 30 mg/kg/d)
Trial: 3323609
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion with somatostatin and hormone replacement (insulin/glucagon/growth hormone)
Trial: 3323609
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion alone
Trial: 29761861
Drug: ICD plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD plus medical therapy
Trial: 25178073
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of nebivolol and amlodipine (n=62)
Trial: 25178073
Drug: Free combination
RxNorm normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free combination of nebivolol and amlodipine (n=62)
Trial: 22863282
Drug: Scheduled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled intravenous analgesia (nurse-administered hydromorphone)
Trial: 14532151
Drug: Rituximab (anti-CD20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (anti-CD20 chimeric monoclonal antibody)
Trial: 8673528
Drug: Didanosine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine 500 mg/d
Trial: 8673528
Drug: Didanosine 200
RxNorm normalized name: didanosine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine 200 mg/d
Trial: 8673528
Drug: Zidovudine 600
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine 600 mg/d
Trial: 1499856
Drug: Intravenous portal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous portal insulin infusion (IPII) via the umbilical vein for 4 months
Trial: 1499856
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) for 4 months
Trial: 6540532
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose prednisolone (60 mg/m2/day p.o. for 21 days)
Trial: 21683660
Drug: Blue light
RxNorm normalized name: Ocuvite Blue Light Mini Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue light therapy (400 lux for 30 minutes per day, Monday through Friday, for 4 weeks)
Trial: 21683660
Drug: Placebo red
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo red light therapy (75 lux)
Trial: 21683660
Drug: Placebo red
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo red light therapy
Trial: 19357997
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% lidocaine with 0.1 mg.kg(‐1) morphine (Group LM)
Trial: 19357997
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% lidocaine with 1.5 mg.kg(‐1) tramadol (Group LT)
Trial: 19357997
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% lidocaine (Group L)
Trial: 17453361
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant endocrine therapy
Trial: 12205826
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (nonfunctioning hearing aid)
Trial: 30540649
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron polysaccharide 150 mg twice daily for 16 weeks
Trial: 29210011
Drug: Um‐PEA 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Um‐PEA 600 mg twice daily
Trial: 26008654
Drug: Oral tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tramadol 100 mg (Group-T, n=30)
Trial: 26008654
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg (Group-F, n=30)
Trial: 17852302
Drug: Multidisciplinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary treatment (including psychological/cognitive-behavioral components)
Trial: 17852302
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (control group of patients who did not start treatment)
Trial: 10929741
Drug: i.v. heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. heparin (5,000 IU bolus + 1,000 IU/h)
Trial: 30861061
Drug: ZTI-01 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZTI-01 (6 g q8h for 7 days)
Trial: 30861061
Drug: Piperacillin-tazobactam (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam (4.5 g IV q8h for 7 days)
Trial: 27773347
Drug: Chewed ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewed ticagrelor tablets
Trial: 27773347
Drug: Crushed ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crushed ticagrelor tablets
Trial: 27773347
Drug: Integral ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integral ticagrelor tablets
Trial: 26373270
Drug: HMB-FA (free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB-FA (free acid form) administered in capsules
Trial: 26373270
Drug: HMB-FA (free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB-FA (free acid form) administered in water
Trial: 26373270
Drug: Ca-HMB (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca-HMB (calcium salt form) administered in capsules
Trial: 26373270
Drug: Ca-HMB (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca-HMB (calcium salt form) administered in water
Trial: 24530134
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group (daily steroids)
Trial: 24530134
Drug: Pulse group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse group (weekly doses of steroids)
Trial: 9444412
Drug: Oral fleroxacin
RxNorm normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fleroxacin 400 mg once a day for 7 days
Trial: 9444412
Drug: Cefalexin 500
RxNorm normalized name: Cefalexin 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefalexin 500 mg three times daily for 7 days
Trial: 2146967
Drug: Caffeine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (75 mg tablets)
Trial: 31792921
Drug: Givosiran 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Givosiran 2.5 mg/kg, administered subcutaneously monthly
Trial: 21477846
Drug: Tinzaparin 175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinzaparin 175 IU/kg once daily
Trial: 28029329
Drug: Dose-adjusted warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-adjusted warfarin for 6 months
Trial: 15832067
Drug: Self-hypnosis (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-hypnosis (mean of 2.4 sessions, SD 1.7; range 2-5 sessions) along with standard anti-allergic pharmacological treatment
Trial: 11981150
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (group C)
Trial: 7621059
Drug: High-dose continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose continuous nebulization of albuterol (7.5 mg/h)
Trial: 7621059
Drug: High-dose intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intermittent nebulization of albuterol (2.5 mg every 20 minutes for four hours)
Trial: 28096
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg clobazam
Trial: 7937568
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg clobazam
Trial: 26727655
Drug: Tocilizumab IV
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab IV 8 mg/kg every 4 weeks over 31 min
Trial: 26727655
Drug: Standard 60-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 60-min infusions of Tocilizumab IV 8 mg/kg every 4 weeks
Trial: 15612979
Drug: SRL-ST (sirolimus-steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRL-ST (sirolimus-steroid regimen without cyclosporine)
Trial: 15612979
Drug: SRL-CsA-ST (sirolimus-cyclosporine-steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRL-CsA-ST (sirolimus-cyclosporine-steroid regimen)
Trial: 12211647
Drug: Vitamin supplementation
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin supplementation (folic acid 5 mg, pyridoxine 40 mg, cyanocobalamin 1 mg once daily)
Trial: 7595106
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment including manipulation
Trial: 98802
Drug: Cigarettes delivering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes delivering 0.2 mg nicotine/cigarette
Trial: 98802
Drug: Cigarettes delivering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes delivering 2.0 mg nicotine/cigarette
Trial: 31162549
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 12.5 mg
Trial: 21795443
Drug: BOLUS (25-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOLUS (25-g dose of whey protein)
Trial: 21795443
Drug: PULSE (ten
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PULSE (ten 2.5-g drinks every 20 min of whey protein)
Trial: 12760903
Drug: Duodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duodenal infusion of 0.1 N hydrochloric acid
Trial: 11115818
Drug: Duodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duodenal infusion of saline
Trial: 3536377
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg methadone
Trial: 8498759
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg methadone (placebo)
Trial: 3561160
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg, iv.)
Trial: 21235477
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SCIT) with D. pteronyssinus extract
Trial: 18155056
Drug: Preemptive epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive epidural analgesia (2 mg morphine in 15 mL of 1% lidocaine)
Trial: 18155056
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal saline in 15 mL)
Trial: 16564436
Drug: Imaginal reliving
RxNorm normalized name: LidoPro Pain Relieving Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaginal reliving in cognitive therapy for PTSD
Trial: 11197521
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments completed by women
Trial: 11197521
Drug: Limitations in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limitations in daily occupations
Trial: 11197521
Drug: Pain variables,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain variables, daily occupations, sick-leave, work variables
Trial: 9088300
Drug: Labored breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labored breathing for twice 30 min (with a 30‐min interval in between)
Trial: 8392957
Drug: Ribavirin (0.8-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (0.8-1.0 g daily)
Trial: 8392957
Drug: Interferon beta
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta (3 MU three times weekly)